Table 2.
Factors associated with the recurrence of HCC after DAA treatment in the overall period
| HCC recurrence | No HCC recurrence | Hazard ratio | 95% CI | p-value | |
|---|---|---|---|---|---|
| Age (years) | 71.9 ± 8.1 | 71.5 ± 8.1 | 1.00 | 0.98–1.03 | 0.71 |
| Sex (male/female) | 70/27 | 56/46 | 1.70 | 1.09–2.66 | 0.013 |
| Body mass index (kg/m2) | 23.1 ± 3.0 | 23.3 ± 3.5 | 0.98 | 0.92–1.05 | 0.79 |
| White blood cell count (/μL) | 4359 ± 1529 | 4235 ± 1207 | 1.00 | 0.99–1.00 | 0.52 |
| Platelet count (×104/μL) | 12.3 ± 10.5 | 11.4 ± 4.6 | 1.00 | 0.98–1.02 | 0.43 |
| ALT (U/L) | 48.9 ± 32.5 | 45.4 ± 28.2 | 1.00 | 0.99–1.00 | 0.42 |
| AST (U/L) | 53.5 ± 25.7 | 51.1 ± 27.6 | 1.00 | 0.99–1.00 | 0.52 |
| Total bilirubin (mg/dL) | 0.8 ± 0.4 | 0.8 ± 0.4 | 0.96 | 0.61–1.52 | 0.89 |
| Albumin (g/dL) | 3.7 ± 0.4 | 3.8 ± 0.4 | 0.68 | 0.42–1.11 | 0.35 |
| Prothrombin time (%) | 83.3 ± 13.9 | 82.6 ± 16.8 | 1.00 | 0.99–1.01 | 0.78 |
| AFP (ng/mL) | 22.5 ± 58.8 | 19.1 ± 46.8 | 1.00 | 0.99–1.00 | 0.65 |
| eGFR (mL/min/1.73 m2) | 66.1 ± 19.5 | 69.1 ± 21.0 | 0.99 | 0.98–1.00 | 0.31 |
| Total cholesterol (mg/dL) | 151 ± 29.0 | 151 ± 26.8 | 1.00 | 0.99–1.00 | 0.96 |
| Diabetes mellitus (no/yes) | 68/28 | 81/21 | 1.43 | 0.92–1.00 | 0.18 |
| Alcohol (none/drinking/unknown) | 69/12/21 | 83/10/4 | 0.90 | 0.59–1.38 | 0.18 |
| FIB-4 index | 5.9 ± 3.8 | 5.7 ± 3.6 | 1.01 | 0.96–1.07 | 0.62 |
| APRI | 1.6 ± 1.5 | 1.5 ± 1.5 | 1.04 | 0.92–1.16 | 0.56 |
| Post-treatment white blood cell count (/μL) | 4845 ± 1434 | 4599 ± 1576 | 1.00 | 0.99–1.00 | 0.26 |
| Post-treatment ALT (U/L) | 21.3 ± 10.3 | 24.1 ± 29.4 | 0.99 | 0.97–1.00 | 0.39 |
| Post-treatment AST (U/L) | 28.8 ± 12.3 | 29.9 ± 19.5 | 0.99 | 0.98–1.00 | 0.64 |
| Post-treatment total bilirubin (mg/dL) | 0.8 ± 0.4 | 0.8 ± 0.3 | 0.98 | 0.60–1.58 | 0.72 |
| Post-treatment albumin (g/dL) | 3.9 ± 0.4 | 3.9 ± 0.3 | 0.76 | 0.48–1.21 | 0.56 |
| Post-treatment prothrombin time (%) | 83.2 ± 14.1 | 83.9 ± 17.2 | 1.00 | 0.98–1.01 | 0.76 |
| Post-treatment AFP (ng/mL) | 9.7 ± 13.0 | 6.4 ± 6.3 | 1.03 | 0.99–1.05 | 0.11 |
| Post-treatment eGFR (mL/min/1.73 m2) | 63.0 ± 18.7 | 67.9 ± 19.8 | 0.98 | 0.97–1.00 | 0.10 |
| SVR/no SVR | 86/11 | 98/4 | 2.55 | 1.35–4.80 | 0.048 |
| Child-Pugh class (A/B/C) | 78/13/1 | 83/13/0 | 1.17 | 0.68–2.02 | 0.58 |
| BCLC stage (0/A/B/C/D) | 37/25/28/16/1 | 44/24/13/19/2 | 1.06 | 0.90–1.25 | 0.75 |
| Number of months from HCC treatment to DAA therapy initiation | 17 ± 25 | 23 ± 26 | 1.00 | 0.99–1.00 | 0.12 |
| Number of curative treatments for HCC | 1.4 ± 1.6 | 0.8 ± 1.3 | 1.23 | 1.09–1.38 | 0.004 |